Thomas F. Gajewski to Signal Transduction
This is a "connection" page, showing publications Thomas F. Gajewski has written about Signal Transduction.
Connection Strength
4.002
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.326
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.313
-
Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108.
Score: 0.263
-
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8.
Score: 0.248
-
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
Score: 0.241
-
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
Score: 0.240
-
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
Score: 0.235
-
Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7.
Score: 0.192
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
Score: 0.183
-
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931.
Score: 0.183
-
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30.
Score: 0.155
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
Score: 0.109
-
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6.
Score: 0.107
-
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
Score: 0.080
-
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
Score: 0.067
-
Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996 Nov 15; 87(4):589-92.
Score: 0.065
-
Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl). 1996 Nov; 74(11):673-83.
Score: 0.065
-
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61.
Score: 0.064
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.063
-
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72.
Score: 0.062
-
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
Score: 0.059
-
Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995 Jun 01; 154(11):5637-48.
Score: 0.059
-
Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
Score: 0.058
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.057
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246.
Score: 0.050
-
Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73.
Score: 0.049
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.043
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.039
-
Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5.
Score: 0.035
-
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102.
Score: 0.035
-
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7.
Score: 0.029
-
CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
Score: 0.023
-
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
Score: 0.020
-
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10.
Score: 0.018
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749.
Score: 0.016
-
Blocked Ras activation in anergic CD4+ T cells. Science. 1996 Mar 01; 271(5253):1276-8.
Score: 0.016
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.016
-
Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol. 1995 Jul; 25(7):1836-42.
Score: 0.015
-
Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1. J Immunol. 1995 May 01; 154(9):4363-70.
Score: 0.015
-
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
Score: 0.014
-
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91.
Score: 0.013
-
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42.
Score: 0.013
-
Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993; 11:29-48.
Score: 0.012
-
Differential activation of murine TH1 and TH2 clones. Res Immunol. 1991 Jan; 142(1):19-23.
Score: 0.011
-
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol. 1990 Jun 01; 144(11):4110-20.
Score: 0.010
-
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
Score: 0.006
-
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42.
Score: 0.005
-
Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998 Aug; 9(2):229-37.
Score: 0.005